Has apotex disclosed its ruxolitinib's fda filing intentions?

Apotex hasn’t (to my knowledge) made any clear, public, official disclosure that specifies its exact FDA filing intentions for a ruxolitinib product (e.g., whether it plans to submit an ANDA/505(b)(2), a specific target filing date, or whether it’s tied to a particular reference product).

What typically happens in the U.S. is that intentions—if they’re disclosed at all—show up in things like:

• FDA “Orange Book” updates after applications are accepted (actual submissions),
• company press releases / investor presentations,
• regulatory or legal filings (e.g., ANDA litigation or patent-case documents),
• patent listing / litigation timelines that indirectly indicate progress.

If you tell me which ruxolitinib product you mean (tablet vs topical, and the brand/reference product name you’re tracking), and whether you’re looking for planned filing vs whether one has already been submitted, I can help you narrow down the best places to check and what the latest public indicators suggest.